<DOC>
	<DOCNO>NCT00920790</DOCNO>
	<brief_summary>To evaluate efficacy , safety pharmacokinetic profile KW-0761 , anti-CC chemokine receptor 4 ( CCR4 ) antibody , administer weekly 8 week intravenous infusion dose 1.0 mg/kg relapsed subject CCR4-positive adult T-cell leukemia-lymphoma .</brief_summary>
	<brief_title>Phase II Study KW-0761 Subjects With CCR4-positive Adult T-cell Leukemia-lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , T-Cell</mesh_term>
	<mesh_term>Leukemia-Lymphoma , Adult T-Cell</mesh_term>
	<criteria>1 . Positive serum antiHTLVI antibody 2 . Acute , lymphoma , chronictype poor prognostic factor specify past 3 . Positive CCR4 4 . Relapsed subject response ( CR , CRu PR ) last previous chemotherapy 5 . Received least one prior chemotherapy 6 . Subjects interval four week last day previous treatment schedule day first KW0761 treatment 7 . PS 0 2 8 . Negative HBs antigen HBVDNA realtime PCR 1 . A history transplantation hematopoietic stem cell 2 . Positive HCV antibody HIV antibody 3 . Active multiple cancer time start clinical study 4 . Previous history allergic reaction receive antibody product 5 . Requiring continuous systemic treatment steroid 6 . Requiring radiotherapy start clinical study 7 . Treated investigational drug KW0761 within three month</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>